Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients
The Angioedema Activity Score (AAS) is recommended by the EAACI/GA2LEN/EDF/WAO guidelines for urticaria as the standard measure for assessing disease activity in patients with recurrent angioedema (RAE). To date, it has been translated into 80 languages for use in 52 countries, but it has not been f...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2019/9157895 |
id |
doaj-b0572caf04e9403ab47870cc6c9ae689 |
---|---|
record_format |
Article |
spelling |
doaj-b0572caf04e9403ab47870cc6c9ae6892020-11-25T00:12:40ZengHindawi LimitedBioMed Research International2314-61332314-61412019-01-01201910.1155/2019/91578959157895Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian PatientsKanokvalai Kulthanan0Leena Chularojanamontri1Chuda Rujitharanawong2Puncharas Weerasubpong3Karsten Weller4Marcus Maurer5Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandDepartment of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandDepartment of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandDepartment of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, ThailandDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité–Universitätsmedizin Berlin, Berlin, GermanyDermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité–Universitätsmedizin Berlin, Berlin, GermanyThe Angioedema Activity Score (AAS) is recommended by the EAACI/GA2LEN/EDF/WAO guidelines for urticaria as the standard measure for assessing disease activity in patients with recurrent angioedema (RAE). To date, it has been translated into 80 languages for use in 52 countries, but it has not been formally validated in Asian patient populations. As RAE may be different in Asian and non-Asian patients, it is important to validate and characterize the reliability of tools to assess RAE disease activity in Asian patients. This study proposed to demonstrate the validity and reliability of the AAS in Asian patients. Accordingly, this study aimed to generate and validate the Thai version of the AAS and to characterize its reliability in Asian patients, specifically in Thailand. A structured translation was conducted with approval from the original authors. The Patient Global Assessment of Disease Activity (PGA-DA) was used as an instrument to compare with the Thai version of the AAS. In total, 86 patients with RAE participated in the study. Seventy-six (88%) patients had RAE with chronic spontaneous urticaria. The Thai AAS was found to be a valid and reliable instrument, with high convergent and known-groups validities, excellent internal consistency, and good test-retest reliability. The validity and reliability of the AAS for assessing RAE disease activity in Asian patients have been demonstrated by our study, making it the first to do so. This will help promote the use of the AAS, in clinical trials and practice, in Asia. It will also facilitate the comparison of disease activity in patients with RAE inside and outside Asia in future studies. However, a limitation of this study was its small number of patients.http://dx.doi.org/10.1155/2019/9157895 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kanokvalai Kulthanan Leena Chularojanamontri Chuda Rujitharanawong Puncharas Weerasubpong Karsten Weller Marcus Maurer |
spellingShingle |
Kanokvalai Kulthanan Leena Chularojanamontri Chuda Rujitharanawong Puncharas Weerasubpong Karsten Weller Marcus Maurer Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients BioMed Research International |
author_facet |
Kanokvalai Kulthanan Leena Chularojanamontri Chuda Rujitharanawong Puncharas Weerasubpong Karsten Weller Marcus Maurer |
author_sort |
Kanokvalai Kulthanan |
title |
Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients |
title_short |
Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients |
title_full |
Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients |
title_fullStr |
Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients |
title_full_unstemmed |
Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients |
title_sort |
angioedema activity score (aas): a valid and reliable tool to use in asian patients |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2019-01-01 |
description |
The Angioedema Activity Score (AAS) is recommended by the EAACI/GA2LEN/EDF/WAO guidelines for urticaria as the standard measure for assessing disease activity in patients with recurrent angioedema (RAE). To date, it has been translated into 80 languages for use in 52 countries, but it has not been formally validated in Asian patient populations. As RAE may be different in Asian and non-Asian patients, it is important to validate and characterize the reliability of tools to assess RAE disease activity in Asian patients. This study proposed to demonstrate the validity and reliability of the AAS in Asian patients. Accordingly, this study aimed to generate and validate the Thai version of the AAS and to characterize its reliability in Asian patients, specifically in Thailand. A structured translation was conducted with approval from the original authors. The Patient Global Assessment of Disease Activity (PGA-DA) was used as an instrument to compare with the Thai version of the AAS. In total, 86 patients with RAE participated in the study. Seventy-six (88%) patients had RAE with chronic spontaneous urticaria. The Thai AAS was found to be a valid and reliable instrument, with high convergent and known-groups validities, excellent internal consistency, and good test-retest reliability. The validity and reliability of the AAS for assessing RAE disease activity in Asian patients have been demonstrated by our study, making it the first to do so. This will help promote the use of the AAS, in clinical trials and practice, in Asia. It will also facilitate the comparison of disease activity in patients with RAE inside and outside Asia in future studies. However, a limitation of this study was its small number of patients. |
url |
http://dx.doi.org/10.1155/2019/9157895 |
work_keys_str_mv |
AT kanokvalaikulthanan angioedemaactivityscoreaasavalidandreliabletooltouseinasianpatients AT leenachularojanamontri angioedemaactivityscoreaasavalidandreliabletooltouseinasianpatients AT chudarujitharanawong angioedemaactivityscoreaasavalidandreliabletooltouseinasianpatients AT puncharasweerasubpong angioedemaactivityscoreaasavalidandreliabletooltouseinasianpatients AT karstenweller angioedemaactivityscoreaasavalidandreliabletooltouseinasianpatients AT marcusmaurer angioedemaactivityscoreaasavalidandreliabletooltouseinasianpatients |
_version_ |
1725398200816238592 |